Clinical Trials Logo

Clinical Trial Summary

The investigators retrospectively analyze the clinical characteristics of severe COVID-19 in our hospital, and then establish a prediction model for long-term complications in patients with severe COVID-19, and strengthen follow-up to improve the prognosis of patients.

Clinical Trial Description

At present, there is a lack of prediction models for the long-term complications of severe COVID-19. Therefore, the investigators used the hospital big data platform to retrospectively analyze the clinical characteristics of severe COVID-19 in our hospital, and conducted cohort follow-up of the changes in lung function including FEV1, FVC,FEV1% and DLCO, etc and and high-resolution CT of patients after discharge. COX model and other statistical methods were used to establish a prediction model for long-term complications of severe COVID-19, and early identification and intervention, strengthen follow-up, and improve the prognosis of patients. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT06235866
Study type Observational
Source Wuhan Central Hospital
Status Enrolling by invitation
Start date February 1, 2024
Completion date November 1, 2025

See also
  Status Clinical Trial Phase
Completed NCT05175833 - Oral Probiotics and Secondary Bacterial Pneumonia in Severe COVID-19 Phase 2
Recruiting NCT05256511 - COVID-19 and VA-LRTI: Second Versus First Wave of the Pandemic
Completed NCT04866082 - Corticosteroids in Severe COVID-19 (ASAP-ESICM/ESAIC Study)
Active, not recruiting NCT04918901 - Comparative Analysis of Clinical Parameters and Radiographic Changes of Severe COVID-19
Recruiting NCT05233605 - Impact of Post-ARDS Covid-19 Sedation on Persistent Neuroinflammation
Not yet recruiting NCT04613986 - Therapeutic Plasma Exchange as an Adjunctive Strategy to Treat Coagulopathy and Inflammation in Severe Covid-19 N/A
Recruiting NCT05447013 - Generation of SARS-CoV-2-specific T Lymphocytes From Recovered Donors and Administration to High-risk COVID-19 Patients Phase 1/Phase 2
Completed NCT04733833 - A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With COVID-19 Phase 2
Recruiting NCT04712344 - Assessment of Efficacy and Safety of Therapy With COVID-19 Convalescent Plasma in Subjects With Severe COVID-19 (IPCO) Phase 2
Terminated NCT04713176 - Efficacy and Safety of DWJ1248 With Remdesivir in Severe COVID-19 Patients Phase 3
Recruiting NCT04648410 - Corticosteroids in Severe COVID-19(ASAP-C Study)
Recruiting NCT05254990 - Reparixin add-on Therapy to Std Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia Phase 3
Completed NCT05596617 - Safety and Efficacy of Medications COVID-19 N/A